Trevena Inc

NASDAQ:TRVN   3:24:43 PM EDT
2.21
-0.02 (-0.90%)
Products, Regulatory

Trevena Announces Completion Of Phase 1 Study For Novel S1p Receptor Modulator

Published: 11/09/2022 13:00 GMT
Trevena Inc (TRVN) - Trevena Announces Completion of Phase 1 Study for Trv045, Novel S1p Receptor Modulator.
Trevena Inc - Nonclinical Study Showed Anti-inflammatory Signaling, Suggesting a Potential Disease-modifying Effect of Trv045 in Treatment of Epilepsy.
Trevena Inc - Pk Profile Supports Anticipated Once Daily Dosing for Trv045.
Trevena Inc - Company is Also Exploring Trv045 As a Potential Treatment for Epilepsy.